8.6379
price down icon2.71%   -0.2121
after-market Handel nachbörslich: 8.64 0.0021 +0.02%
loading
Schlusskurs vom Vortag:
$8.85
Offen:
$9.23
24-Stunden-Volumen:
91,172
Relative Volume:
0.61
Marktkapitalisierung:
$471.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-27.28%
1M Leistung:
-28.43%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$8.33
$9.9848
1-Wochen-Bereich:
Value
$8.225
$12.05
52-Wochen-Spanne:
Value
$8.225
$13.50

Alumis Inc Stock (ALMS) Company Profile

Name
Firmenname
Alumis Inc
Name
Telefon
650-231-6625
Name
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Mitarbeiter
130
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ALMS's Discussions on Twitter

Vergleichen Sie ALMS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ALMS 8.64 471.13M 0 0 0 0.00
VRTX 467.12 119.83B 10.63B -479.80M -1.35B 13.33
REGN 762.38 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 567.35 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.83 24.08B 3.30B -501.07M 1.03B 11.54

Alumis Inc Aktie (ALMS) Neueste Nachrichten

pulisher
02:54 AM

HC Wainwright Has Positive Outlook of Alumis FY2024 Earnings - MarketBeat

02:54 AM
pulisher
02:54 AM

FY2024 EPS Estimates for Alumis Reduced by Leerink Partnrs - MarketBeat

02:54 AM
pulisher
Nov 15, 2024

Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs - TipRanks

Nov 15, 2024
pulisher
Nov 14, 2024

Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Alumis' ESK-001 Shows Promise in Lupus Treatment, New Clinical Data Revealed at ACR 2024 | ALMS Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve

Nov 14, 2024
pulisher
Nov 14, 2024

Towerview LLC Buys 70,000 Shares of Alumis Inc. (NASDAQ:ALMS) - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Alumis (NASDAQ:ALMS) Price Target Lowered to $26.00 at HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Alumis (NASDAQ:ALMS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Alumis Reports 93% Success in Psoriasis Trial, Q3 Loss Widens to $93.1M | ALMS Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 11, 2024

U.S. Energy (NASDAQ:USEG) Earns Sell Rating from Analysts at StockNews.com - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

Chase (NYSE:CCF) Coverage Initiated by Analysts at StockNews.com - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

Analysts Set Alumis Inc. (NASDAQ:ALMS) Price Target at $27.50 - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Eventbrite, Inc. (NYSE:EB) Receives Average Rating of “Hold” from Brokerages - Defense World

Nov 11, 2024
pulisher
Nov 07, 2024

Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Uveitis Clinical Trials 2024: FDA Approvals, Medication, - openPR

Nov 07, 2024
pulisher
Nov 07, 2024

How to Take Advantage of moves in (ALMS) - Stock Traders Daily

Nov 07, 2024
pulisher
Nov 04, 2024

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD - Quantisnow

Nov 04, 2024
pulisher
Nov 04, 2024

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - StockTitan

Nov 04, 2024
pulisher
Nov 03, 2024

Net Present Value Model: Alumis Inc’s ESK-001 - GlobalData

Nov 03, 2024
pulisher
Nov 01, 2024

Alumis (NASDAQ:ALMS) Rating Increased to Strong-Buy at Baird R W - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Oct 31, 2024
pulisher
Oct 31, 2024

Robert W. Baird Begins Coverage on Alumis (NASDAQ:ALMS) - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Baird starts Alumis coverage with Outperform, $25 target - Investing.com India

Oct 31, 2024
pulisher
Oct 30, 2024

Baird starts Alumis coverage with Outperform, $25 target By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 27, 2024

When (ALMS) Moves Investors should Listen - Stock Traders Daily

Oct 27, 2024
pulisher
Oct 26, 2024

Blue Trust Inc. Purchases 307 Shares of Watsco, Inc. (NYSE:WSO) - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - MSN

Oct 25, 2024
pulisher
Oct 23, 2024

Alumis (NASDAQ:ALMS) Stock Price Down 4.5%Time to Sell? - MarketBeat

Oct 23, 2024
pulisher
Oct 21, 2024

Alumis (NASDAQ:ALMS) Trading 3.1% HigherWhat's Next? - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

HC Wainwright Predicts Alumis' Q3 Earnings (NASDAQ:ALMS) - MarketBeat

Oct 21, 2024
pulisher
Oct 20, 2024

Analysts Set Curbline Properties (NYSE:CURB) PT at $24.19 - Defense World

Oct 20, 2024
pulisher
Oct 20, 2024

Ambev (NYSE:ABEV) Now Covered by StockNews.com - Defense World

Oct 20, 2024
pulisher
Oct 17, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside - AOL

Oct 17, 2024
pulisher
Oct 17, 2024

Alumis (NASDAQ:ALMS) Shares Gap UpHere's Why - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

H.C. Wainwright sets Buy rating on Alumis stock, cites TYK2 inhibitor - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

H.C. Wainwright sets Buy rating on Alumis stock By Investing.com - Investing.com UK

Oct 17, 2024
pulisher
Oct 17, 2024

Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

(ALMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies - GlobeNewswire Inc.

Oct 16, 2024
pulisher
Oct 16, 2024

Alumis (NASDAQ:ALMS) Stock Price Down 2.6%What's Next? - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Alumis (NASDAQ:ALMS) Shares Up 6.9%What's Next? - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Millennium Management LLC Takes Position in Alumis Inc. (NASDAQ:ALMS) - MarketBeat

Oct 15, 2024
pulisher
Oct 13, 2024

Squarepoint Ops LLC Has $240,000 Stock Holdings in Forge Global Holdings, Inc. (NYSE:FRGE) - Defense World

Oct 13, 2024
pulisher
Oct 10, 2024

Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' - Benzinga

Oct 10, 2024
pulisher
Oct 08, 2024

Cramer's Lightning Round: 'I like Target right here' - CNBC

Oct 08, 2024
pulisher
Oct 08, 2024

Uveitis Market Growth to Accelerate in Forecast Period - openPR

Oct 08, 2024
pulisher
Oct 08, 2024

Alumis (NASDAQ:ALMS) Trading Up 3.8%Time to Buy? - MarketBeat

Oct 08, 2024
pulisher
Oct 06, 2024

(ALMS) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 06, 2024
pulisher
Oct 04, 2024

Alumis: Could This Broken Immunology IPO Become The Next Amgen? (ALMS) - Seeking Alpha

Oct 04, 2024

Finanzdaten der Alumis Inc-Aktie (ALMS)

Es liegen keine Finanzdaten für Alumis Inc (ALMS) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alumis Inc-Aktie (ALMS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Foresite Capital Management V,
10% Owner
Jul 01 '24
Buy
16.00
2,500,000
40,000,000
5,584,889
Tananbaum James B.
Director
Jul 01 '24
Buy
16.00
2,500,000
40,000,000
5,584,889
$19.00
price up icon 4.27%
$76.98
price up icon 1.23%
$39.53
price up icon 7.03%
$359.21
price down icon 0.88%
$187.76
price down icon 0.58%
$101.83
price up icon 2.00%
Kapitalisierung:     |  Volumen (24h):